Form4insider filings, from the source

SEC Form 4 · accession 0001104659-15-067094

KYTHERA BIOPHARMACEUTICALS INC · KYTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John W Smither
Officer — Chief Financial Officer
Period of report
Sep 23, 2015
Accepted (ET)
Sep 24, 2015 · 9:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockSep 23, 2015M13,272$8.22A16,640D
Common StockSep 23, 2015S13,272$74.90D3,368D
Common StockSep 23, 2015M13,646$27.50A17,014D
Common StockSep 23, 2015S13,646$74.90D3,368D
Common StockSep 24, 2015M13,154$27.50A16,522D
Common StockSep 24, 2015S13,154$74.90D3,368D
Common StockSep 24, 2015M13,763$44.02A17,131D
Common StockSep 24, 2015S13,763$74.90D3,368D
Common StockF3holding———6,216ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionsF1$8.22Sep 23, 2015M13,272D—Feb 1, 2022Common Stock13,2720D
Stock OptionsF2$27.50Sep 23, 2015M13,400D—Jan 29, 2023Common Stock13,4006,700D
Stock OptionsF1$27.50Sep 23, 2015M246D—Jan 29, 2023Common Stock24613,154D
Stock OptionsF1$27.50Sep 24, 2015M13,154D—Jan 29, 2023Common Stock13,1540D
Stock OptionsF2$44.02Sep 24, 2015M13,763D—Jan 22, 2024Common Stock13,76319,266D

Explanation of responses